Navigation Links
Zactima Receives Fast Track Designation By The FDA

ZACTIMA a product of AstraZeneca has been granted fast track designation by the US Food and Drug Administration (FDA). The drug also received the orphan drug designation // recently for treatment of anaplastic, medullary, follicular, locally advanced and metastatic medullary thyroid cancer. Following the approval, investigation of the drug in the treatment of medullary thyroid carcinoma is expected to accelerate further.

Medullary thyroid cancer accounts for 5 to 10% of all thyroid cancers. Surgery, nuclear medicine (treatment with radioactive iodine), hormonal manipulation, external beam radiotherapy (direction of radiation to kill cancer cells from outside the body) and chemotherapy represent some of the available treatment options.

Presently, there is no satisfactory chemotherapy regimen or other treatment modality for the cure of advanced thyroid cancer. Only those drugs, used for the treatment of severe diseases for which there is an unfulfilled medical need would be granted fast-track status by the FDA.

The fast track review by the FDA would be of immense help in the development of the drug and regulation of the submission process. The pharmaceutical company is currently involved in Phase II clinical trials of the drug, directed against metastatic or locally advanced medullary thyroid cancer.

The compound is believed to play a major role in the inhibition of the growth and spread of the thyroid cancer by participating in vital cell signalling pathways. Vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EFGR) participate in the inhibition pathway while REarranged during Transfection (RET) tyrosine kinases can accelerate the growth of the same.

If the treatment is found to be successful, then we might soon have a new treatment modality for the treatment of medullary thyroid cancer.


'"/>




Page: 1

Related medicine news :

1. Fifth US Patient Receives Artificial Heart
2. Northfield Labs Receives FDA Comments
3. British MPs Say Prostate Cancer Receives Low Priority in the NHS
4. Abbott Receives CE Mark Certification
5. East London Receives World Class New Private Hospital Facility
6. Brinda Karat Receives Legal Notice over Ramdev Issue
7. Quake-Hit Pakistan Receives 30 Field Hospitals From Cuba
8. Medtronic’s Insulin Pump Receives Regulatory Approva
9. Aurobindo Receives Approval from USFDA for anti-AIDS drug
10. Sunscreen Blocking UVA Radiation Receives Federal Approval
11. Eddie Thompson Receives Advanced Cancer Treatment
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:12/9/2016)... ... December 09, 2016 , ... Flottman ... and outserts. As a means of expanding capabilities Flottman has added a ... to individually code professional inserts (PIs) and patient package inserts (PPIs) that will ...
(Date:12/9/2016)... , ... December 09, 2016 , ... An inventor from ... to safely ride all types of amusement park rides. , The patent-pending SAFETY STRAP ... is easy to use and could be set up in a matter of minutes, ...
(Date:12/9/2016)... ... December 09, 2016 , ... "I had a terrible time trying ... Va. "I thought that if the nebulizer had a more child-friendly design, then children ... , He developed the patent-pending NEBY to avoid the need to deliver medication via ...
(Date:12/8/2016)... MA (PRWEB) , ... December 08, 2016 , ... ... Workers Compensation Research Institute (WCRI) officially opened registration today for its 33rd ... Hotel in Boston, MA . , The theme of the conference is “Persistent ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... offering Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has ... general counsel and Eric Hoessel to vice president of sales. , Litsinger ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... , Dec 9, 2016 Research ... Screening Market - Forecast to 2021" report to their ... ... of open innovative models in the pharmaceutical and biotechnology industry ... and rising government funding. Emerging markets and growing research activities ...
(Date:12/9/2016)...  RxWiki Inc., a digital health company that powers ... thousands of pharmacies through its Digital Pharmacist SaaS platform, ... "50 on Fire" Award in the Health and Life ... the award as one of Austin,s fastest growing companies," ... RxWiki. "Our platform gives independent retail pharmacies the digital ...
(Date:12/9/2016)... , Dec. 9, 2016  Forge Therapeutics, ... AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) ... ,LpxC, for the treatment of bacterial infections including ... been recognized as an attractive antibacterial target for ... lack of suitable chemical starting points has hampered ...
Breaking Medicine Technology: